Ocular Therapeutix, Inc. $OCUL Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 26.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 720,462 shares of the biopharmaceutical company’s stock after buying an additional 149,359 shares during the period. Peregrine Capital Management LLC owned approximately 0.33% of Ocular Therapeutix worth $6,102,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Millennium Management LLC lifted its position in shares of Ocular Therapeutix by 3,136.1% during the 3rd quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock worth $45,073,000 after purchasing an additional 3,736,560 shares during the last quarter. Alliancebernstein L.P. raised its stake in Ocular Therapeutix by 2,003.2% in the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after buying an additional 3,261,619 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in Ocular Therapeutix by 38.5% in the third quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after buying an additional 2,850,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Ocular Therapeutix by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after buying an additional 2,411,953 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Ocular Therapeutix by 106.5% during the 4th quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock worth $51,321,000 after buying an additional 2,180,702 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

OCUL has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Chardan Capital upped their price objective on shares of Ocular Therapeutix from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Tuesday, April 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and an average price target of $25.11.

Ocular Therapeutix Trading Down 3.6%

NASDAQ OCUL opened at $9.47 on Thursday. The firm’s fifty day moving average is $9.11 and its two-hundred day moving average is $9.68. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. The firm has a market cap of $2.07 billion, a PE ratio of -6.49 and a beta of 0.88.

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $173,479.20. Following the completion of the sale, the insider directly owned 2,597,170 shares of the company’s stock, valued at $21,296,794. This represents a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 28,999 shares of company stock valued at $237,792. Insiders own 3.10% of the company’s stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.